Helicobacter pylori: Difference between revisions

From IDWiki
Helicobacter pylori
()
(Added pathophys and epidemiology, including a map)
Line 3: Line 3:
 
*Slow-growing [[Stain::Gram-negative]] microaerophilic [[Shape::bacillus]] with a curve, gull-wing, or spiral appearance
 
*Slow-growing [[Stain::Gram-negative]] microaerophilic [[Shape::bacillus]] with a curve, gull-wing, or spiral appearance
 
*Oxidase-[[Oxidase::positive]] and urease-[[Urease::positive]]
 
*Oxidase-[[Oxidase::positive]] and urease-[[Urease::positive]]
*Major cause of peptic ulcer disease and gastric cancer
+
*Major cause of peptic ulcer disease and gastric cancer worldwide
  +
  +
=== Pathophysiology ===
  +
*Urease neutrolizes acid and induces angiogenesis
  +
*Strains with CagA, VacA, and BabA are associated with more cellular metaplasia
  +
  +
=== Epidemiology ===
  +
  +
* Present worldwide
  +
* About half of the world's population is estimated to have chronic infection<ref>Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018 Apr;47(7):868-876. doi: [https://doi.org/10.1111/apt.14561 10.1111/apt.14561]. Epub 2018 Feb 12. PMID: [https://pubmed.ncbi.nlm.nih.gov/29430669/ 29430669].</ref>
  +
* Usually acquired during infancy or childhood
  +
* Transmission is likely fecal-oral or oral-oral
  +
  +
[[File:Prevalence of ''Helicobacter pylori'' infection across the world.jpg|thumb|Prevalence of Helicobacter pylori infection across the world. From: Zamani ''et al''. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. ''Aliment Pharmacol Ther''. 2018;47(7):868-876. doi: [https://doi.org/10.1111/apt.14561 10.1111/apt.14561].]]
   
 
==Management==
 
==Management==

Revision as of 09:36, 2 October 2022

Background

  • Slow-growing Gram-negative microaerophilic bacillus with a curve, gull-wing, or spiral appearance
  • Oxidase-positive and urease-positive
  • Major cause of peptic ulcer disease and gastric cancer worldwide

Pathophysiology

  • Urease neutrolizes acid and induces angiogenesis
  • Strains with CagA, VacA, and BabA are associated with more cellular metaplasia

Epidemiology

  • Present worldwide
  • About half of the world's population is estimated to have chronic infection[1]
  • Usually acquired during infancy or childhood
  • Transmission is likely fecal-oral or oral-oral
Prevalence of Helicobacter pylori infection across the world. From: Zamani et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868-876. doi: 10.1111/apt.14561.

Management

  • Treatment is with combination therapy for 14 days followed by confirmation of eradication
  • First-line:
  • Prior treatment failure:
  • Doses:
    • PBMT
      • Bismuth subsalicylate 524 mg (2x 262 mg tablets) PO qid
      • Metronidazole 500 MG PO tid or qid
      • PPI: esomeprazole 20 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, or rabeprazole 20 mg
        • Some areas use double dosing
      • Tetracycline 500 mg PO qid
    • Others
      • Amoxicillin 1000 mg PO bid
      • Clarithromycin 500 mg PO bid
      • Levofloxacin 500 mg PO daily
      • Metronidazole 500 mg PO bid
      • Rifabutin 150 mg PO bid
      • PPI as above
  • Duration: 14 days
  • Confirmation of eradication should be done 4 weeks following treatment
  • Recommended order of treatment, if persistently positive:
    • PBMT (or PAMC)
    • PAMC (or PBMT)
    • PAL
    • PAR vs. repeat endoscopy for culture and susceptibility testing

Further Reading

  1. Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018 Apr;47(7):868-876. doi: 10.1111/apt.14561. Epub 2018 Feb 12. PMID: 29430669.